Baseline demographic and clinical characteristics of patients with or without MACE at 1 year
. | With 1-year MACE n = 65 . | Without 1-year MACE n = 91 . | P . |
|---|---|---|---|
| Age, y, mean ± SD | 66 ± 12 | 63 ± 12 | .16 |
| Age of 80 y, n (%) | 7 (10.8) | 9 (10) | .86 |
| Male, n (%) | 50 (77) | 60 (66) | .14 |
| Ethnicity, n (%) | |||
| White | 39 (60) | 54 (59) | .51 |
| Indo-Asians | 25 (39) | 33 (36) | |
| BMI, kg/m2, mean ± SD | 27 ± 4 | 27 ± 5 | .58 |
| Active smoker, n (%) | 21 (32) | 33 (36) | .61 |
| Family history of CHD, n (%) | 7 (11) | 11 (12) | .80 |
| Medical history since index event | |||
| AMI, n (%) | 58 (89) | 72 (79) | .10 |
| Diabetes, n (%) | 15 (23) | 28 (31) | .29 |
| Hypertension, n (%) | 31 (48) | 39 (43) | .55 |
| Stroke, n (%) | 3 (4.6) | 4 (4.4) | .95 |
| Baseline clinical parameters | |||
| Heart rate, bpm, mean ± SD | 78 ± 15 | 76 ± 14 | .76 |
| Systolic BP, mm Hg, mean ± SD | 130 ± 20 | 133 ± 18 | .35 |
| Killip class 2, n (%) | 22 (34) | 16 (18) | .02 |
| Baseline blood tests | |||
| Total cholesterol, mmol/L, mean ± SD | 5.71 ± 0.9 | 5.73 ± 1.0 | .91 |
| HDL-C, mmol/L, mean ± SD | 1.0 ± 0.14 | 1.0 ± 0.13 | .62 |
| Creatinine, μmol/L, mean ± SD | 90 ± 29 | 89 ± 18 | .79 |
| Glucose, mmol/L, mean ± SD | 7.1 ± 2.6 | 7.6 ± 3.1 | .29 |
| Main ischemic area, n (%) | |||
| Anterior | 39 (60) | 60 (66) | .10 |
| Inferior | 18 (28) | 28 (31) | |
| Lateral | 8 (12) | 3 (3.3) | |
| Baseline TIMI risk score for | |||
| STEMI, mean ± SD | 4.7 ± 1.7 | 3.0 ± 1.9 | .001 |
| Non-STEMI/UAP, mean ± SD | 4.6 ± 0.9 | 3.4 ± 1.5 | .001 |
. | With 1-year MACE n = 65 . | Without 1-year MACE n = 91 . | P . |
|---|---|---|---|
| Age, y, mean ± SD | 66 ± 12 | 63 ± 12 | .16 |
| Age of 80 y, n (%) | 7 (10.8) | 9 (10) | .86 |
| Male, n (%) | 50 (77) | 60 (66) | .14 |
| Ethnicity, n (%) | |||
| White | 39 (60) | 54 (59) | .51 |
| Indo-Asians | 25 (39) | 33 (36) | |
| BMI, kg/m2, mean ± SD | 27 ± 4 | 27 ± 5 | .58 |
| Active smoker, n (%) | 21 (32) | 33 (36) | .61 |
| Family history of CHD, n (%) | 7 (11) | 11 (12) | .80 |
| Medical history since index event | |||
| AMI, n (%) | 58 (89) | 72 (79) | .10 |
| Diabetes, n (%) | 15 (23) | 28 (31) | .29 |
| Hypertension, n (%) | 31 (48) | 39 (43) | .55 |
| Stroke, n (%) | 3 (4.6) | 4 (4.4) | .95 |
| Baseline clinical parameters | |||
| Heart rate, bpm, mean ± SD | 78 ± 15 | 76 ± 14 | .76 |
| Systolic BP, mm Hg, mean ± SD | 130 ± 20 | 133 ± 18 | .35 |
| Killip class 2, n (%) | 22 (34) | 16 (18) | .02 |
| Baseline blood tests | |||
| Total cholesterol, mmol/L, mean ± SD | 5.71 ± 0.9 | 5.73 ± 1.0 | .91 |
| HDL-C, mmol/L, mean ± SD | 1.0 ± 0.14 | 1.0 ± 0.13 | .62 |
| Creatinine, μmol/L, mean ± SD | 90 ± 29 | 89 ± 18 | .79 |
| Glucose, mmol/L, mean ± SD | 7.1 ± 2.6 | 7.6 ± 3.1 | .29 |
| Main ischemic area, n (%) | |||
| Anterior | 39 (60) | 60 (66) | .10 |
| Inferior | 18 (28) | 28 (31) | |
| Lateral | 8 (12) | 3 (3.3) | |
| Baseline TIMI risk score for | |||
| STEMI, mean ± SD | 4.7 ± 1.7 | 3.0 ± 1.9 | .001 |
| Non-STEMI/UAP, mean ± SD | 4.6 ± 0.9 | 3.4 ± 1.5 | .001 |
MACE indicates major adverse cardiovascular events; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TIMI, thrombolysis in myocardial infarction; BP, blood pressure; AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial infarction; UAP, unstable angina pectoris.